IL6 and COVID-19: Interleukin-6 (IL-6) receptor antagonists exhibit anti-inflammatory effects by reducing the elevation of IL-6 (Gordon et al., 2021; Horby et al., 2021; Veiga et al., 2021), and IL-6 is an important mediator for severe systemic inflammatory responses in patients with COVID-19.